The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R1, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
本公开提供了具有式(I)的取代哌啶化合物及其药学上可接受的盐和溶液,其中 R1、B、X 和 Z 的定义如说明书所述。本公开还涉及使用式 I 的化合物治疗对 SMYD 蛋白如 SMYD3 或 SMYD2 的阻断有反应的紊乱。本公开的化合物尤其适用于治疗癌症。
SUBSTITUTED PIPERIDINE COMPOUNDS
申请人:Epizyme, Inc.
公开号:EP3193605A1
公开(公告)日:2017-07-26
Substituted Piperidine Compounds
申请人:EPIZYME, INC.
公开号:US20170362217A1
公开(公告)日:2017-12-21
The present disclosure provides substituted piperidine compounds having Formula (I), and the pharmaceutically acceptable salts and solvates thereof, wherein R
1
, B, X, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of SMYD proteins such as SMYD3 or SMYD2. Compounds of the present disclosure are especially useful for treating cancer.
[EN] CXCR6 INHIBITORS AND METHODS OF USE<br/>[FR] INHIBITEURS DE CXCR6 ET PROCÉDÉS D'UTILISATION
申请人:SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST
公开号:WO2021007208A1
公开(公告)日:2021-01-14
Provided herein are small molecule inhibitors of CXCR6 receptor, compositions comprising the compounds, and methods of using the compounds and compositions. The compounds are 9-azbicyclo[3.3.1]nonane or 9-diazbicyclo[3.3.1]nonane derivatives, whose synthesis is also described. Also provided are method of treating a disease or condition (such as, cancer) mediated by CXCR6/CXCL16 signaling pathway in a mammal.